Eldecalcitol Osteoporosis

Eldecalcitol Osteoporosis drug from Japan. Eldecalcitol is a drug used as a treatment of osteoporosis. "Eldecalcitol is an orally active vitamin D analogue leading to greater absorption of bind calcium."  This drug has been approved for the treatment of osteoporosis in Japan.

Besides regulating calcium metabolism as carried out by conventional vitamin D analogs, eldecalcitol is able to inhibit bone resorption and so it causes a significant increase in bone mineral density. Since elders frequently suffer from low Vitamin D levels, this drug appears to be of special use in this group.

Eldercalcitol Osteoporosis studies.

Eldercalcitol Osteoporosis studies.  There have been several clinical studies of
this drug:

1."In an early Phase II clinical trial, a randomized controlled study with eldecalcitol was conducted with 109 osteoporotic subjects. The patients were assigned randomly to 0.25, 0.5, 0.75, or 1.0 μg/day of eldecalcitol administered via the oral route for 6 months. Eldecalcitol increased lumbar BMD in a dose-dependent manner without causing hypercalcemia or hypercalciuria. Eldecalcitol also exhibited a dose-dependent suppression of a bone resorption marker (urinary deoxypyridinoline) without a significant reduction in osteocalcin."

2. "Based on the results of Phase II clinical studies, a 3-year, randomized, double-blind, active comparator, superiority trial was carried out to compare the effect of eldecalcitol (0.75 μg/day) with that of alfacalcidol (1 μg/day) in preventing fractures in patients with osteoporosis.. . Compared with the alfacalcidol group, the incidence of vertebral fractures was lower in the eldecalcitol group after 36 months of treatment."

3.In the August 2013 issue of Clinical Intervention Aging Japanese researchers
Yuko Noguchi, Hisaya Kawate, Masatoshi Nomura, and Ryoichi Takayanagi published,
"Eldecalcitol for the treatment of osteoporosis".
Some researchers have concluded: "Eldecalcitol has effects on the metabolism of bone and calcium and may prevent falling, so multiple improvements in patients with osteoporosis can be expected with only one drug, which may lead to a reduction in the health care burden. Eldecalcitol would be preferable, especially for elderly people with osteoporosis, because of the high prevalence of vitamin D deficiency."

Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790837/

As of August 2016, this drug is not yet approved for use outside Japan but such
approval may be forthcoming.  If you live outside Japan and are interested in this
drug, I suggest you ask your medical provider about it. You may want to copy the
study cited above or give references to studies on Springer about
Eldecalcitol Osteoporosis.

Click on this link read about drugs other than Eldercalcitol Osteoporosis

Click to read about Natural Bone Building Treatments

Share this page: